Abstract: Ovarian cancer is the leading cause of mortality from gynecological malignancies， chemotherapies and surgical treatments can do litter to cure this malignancy and novel treatment modalities， including immune therapy，are needed.Tumor immune therapy is currently the focus of substantial attention，especially anti-programmed cell death-1/programmed cell death ligand-1（PD-1/PD-L1） treatment.Inthis review， the importance of local tumor immunitywas discussed， which affects the clinical outcome of ovarian cancer. We subsequently provide an overview of the basicfindings regarding how the PD-L1/PD-1 signal influences local tumor immunity in ovarian cancer. Finally， immunotherapy is in a fledging period compared to other traditional therapies，so we discuss what is needed to apply immune therapy in future clinicalmedicine.